SCHEMBL21241884

SCHEMBL21241884

NCC(=O)Nc1nc(-c2ccccn2)cs1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.68
MAPT P10636 5/20 0.68
KDM4E B2RXH2 2/20 0.68
POLB P06746 2/20 0.68
GAA P10253 1/20 0.68
TDP1 Q9NUW8 1/20 0.68
ADORA3 P0DMS8 6/20 0.67
KDM4A O75164 1/20 0.67
KDM4B O94953 1/20 0.67
KDM5B Q9UGL1 1/20 0.67
LMNA P02545 3/20 0.67
HPGD P15428 2/20 0.67
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
ALOX15 P16050 1/20 0.65
WNT3A P56704 1/20 0.65
RAB9A P51151 3/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
NPC1 O15118 1/20 0.64
L3MBTL1 Q9Y468 4/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11786433 0.86 ALDH1A1 (0.68) ALDH1A1MAPTKDM4EPOLBGAA
SCHEMBL4657817 0.85 ADORA3 (0.72) ALDH1A1MAPTKDM4EPOLBGAA
SCHEMBL21506003 0.84 ALDH1A1 (0.65) ALDH1A1MAPTKDM4EPOLBGAA
SCHEMBL21484682 0.83 ALDH1A1 (0.64) ALDH1A1MAPTKDM4EPOLBGAA
SCHEMBL2998083 0.83 ADORA3 (0.79) ALDH1A1MAPTKDM4EPOLBGAA
SCHEMBL21224224 0.82 ELOVL1 (0.72) ALDH1A1MAPTGAAADORA3LMNA
SCHEMBL17716927 0.82 ALDH1A1 (0.75) ALDH1A1MAPTKDM4EPOLBGAA
SCHEMBL18997288 0.82 ADORA3 (0.82) ALDH1A1MAPTKDM4EPOLBGAA
Hydrochloric Acid SCHEMBL21225294 0.81 ELOVL1 (0.71) ALDH1A1MAPTGAAADORA3LMNA
SCHEMBL23714637 0.80 KMT2A (0.48) ALDH1A1MAPTKDM4EPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 US disclosed
CN-112153984-A Compound and use thereof 福宏治疗公司 2020-12-29 CN disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ALDH1A1 2571/4885MAPT 2074/4885KDM4E 1848/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ALDH1A1 2571/4885MAPT 2074/4885KDM4E 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.